These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24405740)

  • 1. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
    BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
    Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
    Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M; van der Reis MI; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
    ; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC
    Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P; Kankaanpää E
    Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H; Li X; Xie F
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 15. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Monigle MC
    Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
    ; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL
    Ophthalmology; 2012 Jul; 119(7):1388-98. PubMed ID: 22555112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.